The Triple A Initiative Study ("Aktionsbündnis Akute Atemnot")
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02049853 |
Recruitment Status :
Terminated
(recruitment numbers lower than expected)
First Posted : January 30, 2014
Last Update Posted : May 20, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Dyspnea Heart Failure | Device: NTproBNP measurement with point of care device "Cobash232" in the POCT group | Not Applicable |
The aim of this prospective, randomized study is to evaluate the effects of point-of-care testing of NT-proBNP in patients presenting with acute dyspnea to the Emergency Medical Service (EMS).Patients will be enrolled in the Emergency Medical Services of participating German hospitals (Klinikum Nürnberg, Klinikum Fürth, Universitätsklinikum Jena). To be enrolled in the study, each patient must meet all of the following inclusion criteria and none of the exclusion criteria.
Patients with acute dyspnea randomized to the POCT group will get a NT-proBNP-POCT measurement in the EMS. The emergency physician of the EMS will decide to apply predefined treatment strategies according to the resulting working hypothesis. Patients with acute dyspnea randomized to the standard care group will NOT get NT-proBNP measurement at the scene. The emergency physician of the ED will construct the working hypothesis following current treatment recommendations. The major focus of the study is to initiate treatment of heart failure as early as possible.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 67 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | A Prospective Randomized Study of Coordinated Diagnostic Pathways and Treatment Algorithms for Patients With Acute Dyspnea Including Point-of-care Testing of a Cardiac Biomarker by the Emergency Medical Service Team |
Study Start Date : | June 2013 |
Actual Primary Completion Date : | April 2015 |
Actual Study Completion Date : | May 2015 |

Arm | Intervention/treatment |
---|---|
No Intervention: default group
Patients with the randomization result "default group" receive standard diagnostics
|
|
Active Comparator: POCT group
patients with the randomization result "POCT group" receive a NTproBNP measurement with point of care device "Cobash232" in the ambulance vehicle
|
Device: NTproBNP measurement with point of care device "Cobash232" in the POCT group |
- Days alive and out of hospital within 30 days [ Time Frame: 30 days ]
- Cost-effectiveness analysis evaluating both costs and effects of alternative therapies (NT-proBNP vs. control group) at day 30, 90 and 180 days [ Time Frame: 60 months ]
- Diagnostic accuracy of chest ultrasound to detect patients with acute heart failure [ Time Frame: 1 month ]
- In-hospital length of stay during follow-up of 30 and 90 days [ Time Frame: 3 months ]
- Improvement of symptoms (dyspnea) 24h, 48h, 72h hours after admission [ Time Frame: 1 month ]
- Need for ICU admission during initial hospitalization [ Time Frame: 6 months ]
- B-type natriuretic peptide level and calculated glomerular filtration rate at discharge [ Time Frame: 6 months ]
- Patients functional status at 30, 90 and 180 days (Barthel Index) [ Time Frame: 6 months ]
- Mortality at 30, 90 and 180 days [ Time Frame: 6 months ]
- Total treatment costs at 30, 90 and 180 days [ Time Frame: 6 months ]
- Days alive and out of hospital at 90 and 180 days [ Time Frame: 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- acute dyspnea (NYHA II-IV)
- age >= 18 years
- informed consent
Exclusion Criteria:
- cardiopulmonary resuscitation < 7 days
- cardiogenic shock, STEMI, respiratory failure, or other clinical conditions that require immediate intensive care admission or angioplasty
- systolic blood pressure lower than 100 mmHg at first contact/presentation
- ventricular tachycardia
- severe aortic stenosis
- advanced neoplasm (e.g. lung cancer, hematologic neoplasm, etc.)
- chronic kidney disease requiring hemodialysis

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02049853
Germany | |
Klinikum Nürnberg | |
Nuremberg, Bavaria, Germany, 90419 | |
Bayrisches Rotes Kreuz | |
Fürth, Germany, 90762 | |
Klinikum Fürth, Emergency Department | |
Fürth, Germany, 90766 | |
Universitätsklinikum Jena, Department of Anesthesiology and Intensive Care Medicine | |
Jena, Germany, 07747 | |
DRK-Kreisverbandes Jena-Eisenberg-Stadtroda e.V. | |
Jena, Germany, 07749 | |
Johanniter-Unfall-Hilfe | |
Nuremberg, Germany, 90419 |
Principal Investigator: | Michael Christ, Prof. | Klinikum Nürnberg |
Responsible Party: | Prof. Dr. Michael Christ, Prof. Dr. med. Michael Christ, Klinikum Nürnberg |
ClinicalTrials.gov Identifier: | NCT02049853 |
Other Study ID Numbers: |
TripleA01 |
First Posted: | January 30, 2014 Key Record Dates |
Last Update Posted: | May 20, 2015 |
Last Verified: | May 2015 |
acute dyspnea heart failure diagnostics POCT analysis preclinical area |
Dyspnea Heart Failure Heart Diseases Cardiovascular Diseases |
Respiration Disorders Respiratory Tract Diseases Signs and Symptoms, Respiratory |